WO2004032825A2 - Use of 2,3 alkylcarbonyloxybenzoic acids in the treatment of anthrax - Google Patents

Use of 2,3 alkylcarbonyloxybenzoic acids in the treatment of anthrax Download PDF

Info

Publication number
WO2004032825A2
WO2004032825A2 PCT/US2002/035056 US0235056W WO2004032825A2 WO 2004032825 A2 WO2004032825 A2 WO 2004032825A2 US 0235056 W US0235056 W US 0235056W WO 2004032825 A2 WO2004032825 A2 WO 2004032825A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkylcarbonyloxybenzoic
acid
subject
amount
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/035056
Other languages
French (fr)
Other versions
WO2004032825A3 (en
Inventor
Karen J. Stec
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Life Sciences Inc
Original Assignee
Advanced Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Life Sciences Inc filed Critical Advanced Life Sciences Inc
Priority to AU2002368208A priority Critical patent/AU2002368208A1/en
Publication of WO2004032825A2 publication Critical patent/WO2004032825A2/en
Anticipated expiration legal-status Critical
Publication of WO2004032825A3 publication Critical patent/WO2004032825A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Definitions

  • This invention is directed to the field of treating anthrax. More particularly, this invention is directed to the field of repairing damage to tissue such as lung tissue caused by the Bacillus anthracis bacterium.
  • Inhalation anthrax is a disease resulting from inhalation of spores of the bacterium Bacillus anthracis.
  • the spores are the dormant form of the bacterium.
  • the bacteria multiply and produce toxins. These toxins cause inflammation, fluid buildup and hemorrhaging in the lungs, followed in most cases by rapid death.
  • the anthrax toxins were considered to be the cause of the vascular damage, resulting in the fluid buildup and hemorrhaging.
  • the toxins were found to have three components: protective antigen, edema factor, and lethal factor.
  • protective antigen edema factor
  • lethal factor edema factor
  • Certain antibiotics are known to prevent inhalation anthrax, but only if the antibiotics are administered prior to spore germination in the lungs. There presently are no known therapeutic agents for the treatment for inhalation anthrax once lung activity has begun. This is especially problematic in that early symptoms of inhalation anthrax resemble flu symptoms. When anthrax enters the secondary stage, death of the subjects is near certain, generally resulting from the vascular permeability and resulting pulmonary edemas caused by the toxins. Even if antibiotics are used effectively in treatment, there has been no method reported for reversing the above-described lung damage.
  • the present invention is directed to such a therapeutic agent.
  • the invention encompasses methods for treating inhalation anthrax by the use of 2,3- alkylcarbonyloxybenzoic acids in which the alkylcarbonyloxy group has 2-18 carbon atoms.
  • One particularly preferred compound is 2,3-diacetoxybenzoic'acid.
  • the preferred method of treatment involves administering 2,3-alkylcarbonyloxybenzoic acid to a subject known or suspected to have inhalation anthrax.
  • the 2,3-alkylcarbonyloxybenzoic acid can be administered by any known therapeutic method, and in combination with other compounds known or believed to prevent or treat anthrax. More than one of the 2,3- alkylcarbonyloxybenzoic acid compounds can also be blended.
  • a therapeutic ally effective amount of a compound selected from the group consisting of 2,3-alkylcarbonyloxybenzoic acids and salts thereof in which the alkylcarbonyloxy group has 2-18 carbon atoms is administered to subjects who have indications for inhalation anthrax.
  • any reference to 2,3- alkylcarbonyloxybenzoic acids shall be construed to include the salts thereof.
  • the 2,3- alkylcarbonyloxybenzoic acids have been shown to ameliorate the damage resulting from increased vascular permeability and the resulting pulmonary edema caused by increased microvascular permeability to protein and solutes resulting from Adult Respiratory Distress Syndrome and sepsis. This effect is detailed in U.S. Patent No. 5,504,111, issued April 2, 1996 to Flavin et al.
  • a particularly prefe ⁇ -ed compound in the class of 2,3-alkylcarbonyloxybenzoic acid compounds is 2,3-diacetoxybenzoic acid.
  • 2,3- diacetoxybenzoic acid is administered to a subject, either via intravenous or aerosol spray means in a therapeutically effective amount. This amount is preferably, but not exclusively, in the range of 1-100 mg/kg of body weight of the subject. More preferably, the range is 5-
  • the range is 5-20 mg/kg of body weight.
  • anthrax treatment product may also comprise 2,3-dihydroxybenzoic acid, whether administered directly or through chemical conversion in the subject.
  • the 2,3-alkylcarbonyloxybenzoic acid can be used either on a' preventative basis, or after anthrax disease has been diagnosed, either in the initial or secondary stage of diagnosis.
  • the 2,3-alkylcarbonyloxybenzoic acid can be administered to human or animal subjects.
  • the 2,3-alkylcarbonyloxybenzoic acid is typically produced in solid form.
  • it is preferably formulated into a liquid form by use of a sodium bicarbonate buffer present in an amount to effectively solubilize and stabilize the acid.
  • the acid is also converted to a sodium salt.
  • the buffered salt can then be constituted into aerosol form using conventional methods of forming aerosol products. Administration of the aerosol form can be accomplished via either nasally or orally, including forms such as metered inhaled forms.
  • 2,3-alkylcarbonyloxybenzoic acid Treatment with 2,3-alkylcarbonyloxybenzoic acid can be used as a sole treatment mechanism, or in combination with other therapeutic agents.
  • 2,3- alkylcarbonyloxybenzoic acid can be administered in conjunction with antibiotic therapy.
  • Antiobiotics have been shown to treat the Bacillus anthracis bacterium, but not the damage caused by the toxins produced by the bacteria.
  • a combination of 2,3- alkylcarbonyloxybenzoic acid and one or more antibiotics is expected to be an especially useful therapeutic combination.
  • the antibiotics may be selected from the group comprising ciprofloxacin, doxycycline, rifampin, vancomycin, imipenem, chloramphenicol, penicillin, clindamycin, clarithromycin, and analogs, homologs, and derivatives thereof which have antibiotic functionality.
  • 2,3-alkylcarbonyloxybenzoic acid can also be combined with other therapeutic agents which are used in the treatment of sepsis or other conditions in which bacteria and their toxins spread through lung tissues.
  • An example of such a therapeutic agent is drotrecogin alfa (Xigris ® brand, Eli Lilly & Co.), but any similar therapeutic agents also can be used.
  • a benefit of co-treatment with drotrecogin alfa is that the mechanism of drotrecogin alfa differs from that of 2,3-alkylcarbonyloxybenzoic acid.
  • the present invention teaches a novel method for the treatment of inhalation anthrax, and the novel use of 2,3-alkylcarbonyloxybenzoic acids and salts thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for treating inhalation anthrax is disclosed. The inventive method comprises the use of 2,3-alkylcarbonyloxybenzoic acid and salts thereof in the prevention and treatment of lung damage caused by Bacillus anthracis and toxins produced by the bacterium. The 2,3-alkylcarbonyloxybenzoic acid may be used alone or in combination with other therapeutic agents such as antibiotics.

Description

TITLE
USE OF 2,3 ALKYLCARBONYLOXYBENZOIC ACIDS IN THE TREATMENT OF ANTHRAX
This application claims the benefit of U.S. Provisional Patent Application No. 60/336,006, filed on November 2, 2002.
FIELD OF THE INVENTION
This invention is directed to the field of treating anthrax. More particularly, this invention is directed to the field of repairing damage to tissue such as lung tissue caused by the Bacillus anthracis bacterium.
BACKGROUND OF THE INVENTION
Inhalation anthrax is a disease resulting from inhalation of spores of the bacterium Bacillus anthracis. The spores are the dormant form of the bacterium. However, upon germination in the lungs of human or animal subjects, the spores become active. Very rapidly following germination, the bacteria multiply and produce toxins. These toxins cause inflammation, fluid buildup and hemorrhaging in the lungs, followed in most cases by rapid death.
There have been studies of the manifestations of anthrax in the lungs. One such study was published in the Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 2291-2294, March , 1993 by Faina A. Abramova et al ("Abramova"). In this study, autopsies of 42 subjects who died of inhalation anthrax were conducted. All of the subjects were found to have hemorrhagic necrosis of the thoracic lymph nodes in the lymphatic drainage of the lungs and hemorrhagic mediastinitis. The lungs of the subjects also evidenced edema and increased vascular permeability. The anthrax toxins were considered to be the cause of the vascular damage, resulting in the fluid buildup and hemorrhaging. The toxins were found to have three components: protective antigen, edema factor, and lethal factor. Generally, the mechanism of antlirax in the lungs appear to be similar to manifestations of sepsis.
Certain antibiotics are known to prevent inhalation anthrax, but only if the antibiotics are administered prior to spore germination in the lungs. There presently are no known therapeutic agents for the treatment for inhalation anthrax once lung activity has begun. This is especially problematic in that early symptoms of inhalation anthrax resemble flu symptoms. When anthrax enters the secondary stage, death of the subjects is near certain, generally resulting from the vascular permeability and resulting pulmonary edemas caused by the toxins. Even if antibiotics are used effectively in treatment, there has been no method reported for reversing the above-described lung damage.
Thus, there is a need for a therapeutic agent for the treatment of inhalation anthrax. The present invention is directed to such a therapeutic agent.
SUMMARY OF THE INVENTION
The invention encompasses methods for treating inhalation anthrax by the use of 2,3- alkylcarbonyloxybenzoic acids in which the alkylcarbonyloxy group has 2-18 carbon atoms. One particularly preferred compound is 2,3-diacetoxybenzoic'acid. The preferred method of treatment involves administering 2,3-alkylcarbonyloxybenzoic acid to a subject known or suspected to have inhalation anthrax. The 2,3-alkylcarbonyloxybenzoic acid can be administered by any known therapeutic method, and in combination with other compounds known or believed to prevent or treat anthrax. More than one of the 2,3- alkylcarbonyloxybenzoic acid compounds can also be blended.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
In a preferred embodiment, a therapeutic ally effective amount of a compound selected from the group consisting of 2,3-alkylcarbonyloxybenzoic acids and salts thereof in which the alkylcarbonyloxy group has 2-18 carbon atoms is administered to subjects who have indications for inhalation anthrax. (For purposes of this application, any reference to 2,3- alkylcarbonyloxybenzoic acids shall be construed to include the salts thereof.) The 2,3- alkylcarbonyloxybenzoic acids have been shown to ameliorate the damage resulting from increased vascular permeability and the resulting pulmonary edema caused by increased microvascular permeability to protein and solutes resulting from Adult Respiratory Distress Syndrome and sepsis. This effect is detailed in U.S. Patent No. 5,504,111, issued April 2, 1996 to Flavin et al.
A particularly prefeπ-ed compound in the class of 2,3-alkylcarbonyloxybenzoic acid compounds is 2,3-diacetoxybenzoic acid. In an especially preferred embodiment, 2,3- diacetoxybenzoic acid is administered to a subject, either via intravenous or aerosol spray means in a therapeutically effective amount. This amount is preferably, but not exclusively, in the range of 1-100 mg/kg of body weight of the subject. More preferably, the range is 5-
50 mg/kg of body weight, and most preferably, the range is 5-20 mg/kg of body weight.
While preferred, these ranges are exemplary only. Combinations with other therapeutic agents, the delivery system, and the stage of the anthrax disease may result in use of amounts outside the above-described ranges. The dosages described above can be administered over the period of time necessary to show effectiveness. While not wishing to be bound by theory, it is believed that, following administration to a subject, at least a percentage of 2,3-diacetoxybenzoic acid is converted to 2,3-dihydroxybenzoic acid, which has therapeutic effectiveness. Thus, all or a portion of an anthrax treatment product may also comprise 2,3-dihydroxybenzoic acid, whether administered directly or through chemical conversion in the subject.
The 2,3-alkylcarbonyloxybenzoic acid can be used either on a' preventative basis, or after anthrax disease has been diagnosed, either in the initial or secondary stage of diagnosis. The 2,3-alkylcarbonyloxybenzoic acid can be administered to human or animal subjects.
The 2,3-alkylcarbonyloxybenzoic acid is typically produced in solid form. In preparing the therapeutic product, it is preferably formulated into a liquid form by use of a sodium bicarbonate buffer present in an amount to effectively solubilize and stabilize the acid. The acid is also converted to a sodium salt. The buffered salt can then be constituted into aerosol form using conventional methods of forming aerosol products. Administration of the aerosol form can be accomplished via either nasally or orally, including forms such as metered inhaled forms.
Treatment with 2,3-alkylcarbonyloxybenzoic acid can be used as a sole treatment mechanism, or in combination with other therapeutic agents. For example, 2,3- alkylcarbonyloxybenzoic acid can be administered in conjunction with antibiotic therapy. Antiobiotics have been shown to treat the Bacillus anthracis bacterium, but not the damage caused by the toxins produced by the bacteria. Thus, a combination of 2,3- alkylcarbonyloxybenzoic acid and one or more antibiotics is expected to be an especially useful therapeutic combination. The antibiotics may be selected from the group comprising ciprofloxacin, doxycycline, rifampin, vancomycin, imipenem, chloramphenicol, penicillin, clindamycin, clarithromycin, and analogs, homologs, and derivatives thereof which have antibiotic functionality.
2,3-alkylcarbonyloxybenzoic acid can also be combined with other therapeutic agents which are used in the treatment of sepsis or other conditions in which bacteria and their toxins spread through lung tissues. An example of such a therapeutic agent is drotrecogin alfa (Xigris ® brand, Eli Lilly & Co.), but any similar therapeutic agents also can be used. A benefit of co-treatment with drotrecogin alfa is that the mechanism of drotrecogin alfa differs from that of 2,3-alkylcarbonyloxybenzoic acid.
Thus, the present invention teaches a novel method for the treatment of inhalation anthrax, and the novel use of 2,3-alkylcarbonyloxybenzoic acids and salts thereof.

Claims

WHAT IS CLAIMED IS:
1. A method for treating inhalation antlirax comprising administering to a human or animal subject an effective therapeutic amount of one or more compounds selected from the group consisting of 2,3-alkylcarbonyloxybenzoic acids and salts thereof wherein the alkylcarbonyl group has 2-18 carbon atoms.
2. The method of claim 1 wherein said 2,3-alkylcarbonyloxybenzoic acid is 2,3- diacetoxybenzoic acid.
3. The method of claim 1 wherein said 2,3-alkylcarbonyloxybenzoic acid is formulated in liquid form in the presence of a buffer.
4. The method of claim 3 wherein said buffer is a sodium bicarbonate buffer such that a sodium salt of said 2,3-alkylcarbonyloxybenzoic acid is formed.
5. The method of claim 1 wherein said 2,3-alkylcarbonyloxybenzoic acid is administered to said subject in aerosol spray form.
6. The method of claim 5 wherein said 2,3-alkylcarbonyloxybenzoic acid is administered via nasal or mouth passages.
7. The method of claim 1 wherein said 2,3-alkylcarbonyloxybenzoic acid is administered to said subject in liquid form via intravenous means.
8. The method of claim 1 wherein said 2,3-alkylcarbonyloxybenzoic acid is administered to said subject together with an antibiotic.
9. The method of claim 8 wherein said antibiotic is selected from the group comprising ciprofloxacin, doxycycline, rifampin, vancomycin, imipenem, chloramphenicol, penicillin, clindamycin, clarithromycin, and analogs, homologs, and derivatives thereof which have antibiotic functionality.
10. The method of claim 1 wherein said 2,3-alkylcarbonyloxybenzoic acid is administered to said subject together with at least one therapeutic agent for the
, treatment of sepsis.
11. The method of claim 10 wherein said therapeutic agent for the treatment of sepsis is drotrecogin alfa.
12. The method of claim 1 wherein said 2,3-alkylcarbonyloxybenzoic acid is administered in an amount of from about 1 mg. to about 100 mg. per kg. of body weight of said subject.
13. The method of claim 12 wherein said 2,3-alkylcarbonyloxybenzoic acid is administered in an amount of from about 5 mg. to about 50 mg. per kg. of body weight of said subject.
14. The method of claim 13 wherein said 2,3-alkylcarbonyloxybenzoic acid is administered in an amount of from about 5 mg. to about 20 mg. per kg. of body weight of said subject.
15. The use in an effective therapeutic amount of one or more compounds selected from the group consisting of 2,3-alkylcarbonyloxybenzoic acids and salts thereof in which the alkylcarbonyl group has 2-18 carbon atoms in the treatment of inhalation anthrax.
16. The use of claim 15 wherein said 2,3-alkylcarbonyloxybenzoic acid is 2,3- diacetoxybenzoic acid.
17. The use of claim 15 wherein said effective therapeutic amount is an amount of from about 1 mg. to about 100 mg. per kg. of body weight of said subject.
18. The use of claim 17 wherein said effective therapeutic amount is an amount of from about 5 mg. to about 50 mg. per kg. of body weight of said subject.
19. The use of claim 18 wherein said effective therapeutic amount is an amount of from about 5 mg. to about 20 mg. per kg. of body weight of said subject.
20. The use in an effective therapeutic amount of one or more compounds selected from the group consisting of 2,3-alkylcarbonyloxybenzoic acids and salts thereof in which the alkylcarbonyl group has 2-18 carbon atoms combined with an effective therapeutic amount of one or more antibiotics in the treatment of inhalation anthrax.
21. The use of claim 20 wherein said antibiotics are selected from the group comprising ciprofloxacin, doxycycline, rifampin, vancomycin, imipenem, chloramphenicol, penicillin, clindamycin, clarithromycin, and analogs, homologs, and derivatives thereof which have antibiotic functionality.
22. The use of Claim 15 in an effective therapeutic amount of one or more compounds selected from the group consisting of 2,3-alkylcarbonyloxybenzoic acids and salts thereof in which the alkylcarbonyl group has 2-18 carbon atoms combined with an effective therapeutic amount of at least one therapeutic agent for the treatment of sepsis.
23. The use of claim 22 wherein said therapeutic agent for the treatment of sepsis is drotrecogin alfa.
PCT/US2002/035056 2001-11-02 2002-10-31 Use of 2,3 alkylcarbonyloxybenzoic acids in the treatment of anthrax Ceased WO2004032825A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002368208A AU2002368208A1 (en) 2001-11-02 2002-10-31 Use of 2,3 alkylcarbonyloxybenzoic acids in the treatment of anthrax

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33600601P 2001-11-02 2001-11-02
US60/336,006 2001-11-02

Publications (2)

Publication Number Publication Date
WO2004032825A2 true WO2004032825A2 (en) 2004-04-22
WO2004032825A3 WO2004032825A3 (en) 2004-12-02

Family

ID=32093654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035056 Ceased WO2004032825A2 (en) 2001-11-02 2002-10-31 Use of 2,3 alkylcarbonyloxybenzoic acids in the treatment of anthrax

Country Status (3)

Country Link
US (1) US20040029783A1 (en)
AU (1) AU2002368208A1 (en)
WO (1) WO2004032825A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6063121B2 (en) * 2011-12-26 2017-01-18 任天堂株式会社 Communication system, communication terminal, communication method and program

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK483587D0 (en) * 1987-09-15 1987-09-15 Riemann & Co Aps Claus ANTIPERSPIRANT PREPARATION
US5504111A (en) * 1994-12-30 1996-04-02 Medichem Research, Inc. Use of 2,3 alkylcarbonyloxybenzoic acid in treating adult respiratory distress syndrome
US5744453A (en) * 1996-01-05 1998-04-28 Mintz; Clifford S. Polyamine conjugates for treatment of infection

Also Published As

Publication number Publication date
AU2002368208A1 (en) 2004-05-04
WO2004032825A3 (en) 2004-12-02
US20040029783A1 (en) 2004-02-12
AU2002368208A8 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
EP4125802B1 (en) 5-amino-2,3-dihydro-1,4-phthalazinedione for treatment of acute lung injury
KR101862415B1 (en) Synergistic antiviral composition and use thereof
JP7798858B2 (en) Compounds for the treatment of coronavirus infections
CZ299348B6 (en) Aerosol formulation
JP6234899B2 (en) Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
JP2023513106A (en) Nitric oxide releasing antimicrobial compounds, formulations, and methods associated therewith
RS63639B1 (en) BETA-HAIRPILL PEPTIDOMIMETIC WITH ELASTASE INHIBITOR ACTIVITY AND ITS AEROSOL DOSAGE FORMS
CN116963738A (en) Luminol for the prevention and treatment of sequelae of SARS-CoV-2 infection
KR20100117148A (en) Treatment of lung disorder
US20040029783A1 (en) Use of 2,3 alkylcarbonyloxybenzoic acids in the treatment of anthrax
JP2022537792A (en) Compositions and synergistic methods for treating infections
US12440488B2 (en) Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension
Al-Kamarany et al. Pharmacological and Therapeutic Features of COVID-19 Infection in Hodeidah, Yemen
US20230201309A1 (en) Compositions for the treatment of a respiratory condition
JP2011513356A (en) Combination therapy
ZA200503711B (en) An aqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture for use by nasal administration in treating thromboembolism
US20220273594A1 (en) Compositions and Use of N-Chlorotaurine for Treatment and Prevention of Respiratory Infections
CN102369012B (en) Use of deuterium oxide for the treatment of viral respiratory diseases
RS51082B (en) SYNERGISTIC COMBINATION INCLUDING ROFLUMILAS AND (R.R.) -FORMOTEROL
EP3906934A1 (en) Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections
García Canclini et al. Ibuprofen, a traditional drug that may impact the course of COVID-19 new effective formulation in nebulizable solution
WO2025067689A1 (en) 5-amino-2,3-dihydro-1,4-phthalazinedione for the treatment of infections with an rna virus
US20040157772A1 (en) Use of a gatran for the manufacture of a medicament of the treatment of pulmonary fibrosis
EA052469B1 (en) TREATMENT OF NON-CYSTIC FIBROUS (NON-MUCOVISCIDOSIS) BRONCHIOECTASIS
PROFILE EN 241104, GS 4104, RO 640796, Tamiflu

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP